Cargando…

Tracking the tail

Immune-checkpoint inhibitors have deeply changed the therapeutic landscape of advanced non-small cell lung cancer without actionable genomic alterations. Immune-checkpoint inhibitors have become standard front-line therapy, especially among patients with tumours expressing high levels of programmed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedlaender, Alex, Liu, Stephen V, Addeo, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473618/ https://www.ncbi.nlm.nih.gov/pubmed/32883870 http://dx.doi.org/10.1136/jitc-2020-000971

Ejemplares similares

COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
por: Mederos, Nuria, et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy: A Promising New Standard of Care
por: Boydell, Emma, et al.
Publicado: (2023)

Cancer and COVID-19: Unmasking their ties
por: Addeo, A., et al.
Publicado: (2020)

Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer
por: Addeo, Raffaele
Publicado: (2021)

A Tail of Multiple Calcium-sensing Domains
por: Salkoff, Lawrence
Publicado: (2006)

Twisting tails exposed: the evidence for TCR conformational change
por: Levin, Susan E., et al.
Publicado: (2005)

A tale of an A-tail: The lifeline of a SINE
por: Roy-Engel, Astrid M.
Publicado: (2012)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others
por: Wheatley, Adam K, et al.
Publicado: (2016)

Brown fat and vascular heat dissipation: The new cautionary tail
por: Warner, Amy, et al.
Publicado: (2014)

Beyond the histone tail: Acetylation at the nucleosome dyad commands transcription
por: Molina-Serrano, Diego, et al.
Publicado: (2013)

Tying Metabolic Branches With Histone Tails Using Systems Biology
por: Chandrasekaran, Sriram
Publicado: (2019)

The tail of cryptochromes: an intrinsically disordered cog within the mammalian circadian clock
por: Parico, Gian Carlo G., et al.
Publicado: (2020)

Predicting Risk at the End of the End: Telomere G-tail as a Biomarker
por: Seimiya, Hiroyuki
Publicado: (2015)

Capturing Ion Channel Gating: A Little Salt on the Tail Does the Trick
por: Zimmerman, Anita L.
Publicado: (2004)

When the tail can't wag the dog: the implications of CNS-intrinsic initiation of neuroinflammation
por: Davis, Deirdre S, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_5s2sn5ctj1q5rlub3dclnp6sq0